Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
about
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?The role of taxanes in triple-negative breast cancer: literature reviewAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsA phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastasesStrong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer.Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study.G-protein coupled receptors of the renin-angiotensin system: new targets against breast cancer?Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval.Weekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion.Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialLong-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer.Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials.Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer.Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research.Molecularly targeted therapies for metastatic triple-negative breast cancer.Safety and efficacy evaluation of albumin-bound paclitaxel.A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung CancerWhat Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near Future
P2860
Q26745420-96240F84-DA5B-40A6-92D2-AB7C9E152206Q26798356-DF706D06-D606-4BBD-AFB8-3C96D6E412A9Q26798674-33BF97C3-F8CF-4CD2-9CB9-8A752054E68DQ33405667-3270EBA4-62B8-4290-BB04-0ACEDB66411AQ33628383-9DFDC376-5D50-492D-B9DC-9830CE06FA04Q34570508-0ED27230-0090-4939-9E19-E6B58C2ACD34Q35089791-0ABFACE9-AE36-4033-9C1E-D88B98231785Q35128729-908245BD-445A-437F-BC4F-CAFD229FCBC8Q36036125-25E741C6-96CA-4566-8CDA-46382DD20B2FQ36326026-8FE17113-754E-4302-B0D9-B91F176B5D3DQ36379813-28CEE0AD-96CD-405E-B49F-2FE3630D25D2Q36551346-BB46ED00-3425-45E6-A90B-5B13FD0F932BQ37078553-6F0E434D-0A11-4881-A4C1-22C7B7F809EAQ37360151-E00F7996-E9BC-4501-964C-8DBDDDD32EE4Q37659713-CEEC8461-CC09-466A-832C-4B013D577967Q37725620-420FE8BA-9422-45FF-BBB3-3460B7E4D2D5Q37960507-408DED6C-609B-4B7B-8E02-9786E8111458Q37977498-E723D4EB-0639-45CB-9AFB-2CBE50357B5FQ37981001-AE8E05EE-CF9E-495B-A6BE-19EF16A277BEQ38077472-8134433D-E93E-4ACB-962B-5CE4836A806BQ38190090-EB0A9772-BE9C-4C1A-806D-2D3CD9BDB696Q38433690-8156ABC7-262E-4A3D-AF61-2AD0F035E4FBQ38946259-1D8A94BA-9D90-4064-9BBE-ED5FBE495033Q39243591-E5DDA41D-691D-42BB-B476-4954DD8BE373Q41536996-939453BB-4253-47F3-BA81-BAB95333AE35Q59128232-8DA2AE6C-B43A-4205-BE26-EB74D6BB9D10
P2860
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Final results of a phase II st ...... tive metastatic breast cancer.
@ast
Final results of a phase II st ...... tive metastatic breast cancer.
@en
type
label
Final results of a phase II st ...... tive metastatic breast cancer.
@ast
Final results of a phase II st ...... tive metastatic breast cancer.
@en
prefLabel
Final results of a phase II st ...... tive metastatic breast cancer.
@ast
Final results of a phase II st ...... tive metastatic breast cancer.
@en
P2093
P1476
Final results of a phase II st ...... tive metastatic breast cancer.
@en
P2093
Annapoorna Ferrell
Aurelio Castrellon
Catherine Welsh
Christopher Lobo
Connie Higgins
Erin Hurley
Gilberto Lopes
Isildinha Reis
Joyce Slingerland
Judith Hurley
P2888
P304
P356
10.1007/S10549-010-1002-0
P407
P577
2010-06-29T00:00:00Z
P5875
P6179
1031492889